Novo Nordisk’s obesity drug CagriSema helps obese patients cut weight by 22.7%: Report | Company Business News
The new findings from the drug candidate deals a blow to the Danish drugmaker’s ambitions for a successor to its popular Wegovy more powerful than Eli Lilly’s Zepbound.
